- Brazil
- /
- Healthcare Services
- /
- BOVESPA:PARD3
Investor Optimism Abounds Instituto Hermes Pardini S.A. (BVMF:PARD3) But Growth Is Lacking
With a price-to-earnings (or "P/E") ratio of 26x Instituto Hermes Pardini S.A. (BVMF:PARD3) may be sending very bearish signals at the moment, given that almost half of all companies in Brazil have P/E ratios under 16x and even P/E's lower than 9x are not unusual. Although, it's not wise to just take the P/E at face value as there may be an explanation why it's so lofty.
With earnings growth that's superior to most other companies of late, Instituto Hermes Pardini has been doing relatively well. It seems that many are expecting the strong earnings performance to persist, which has raised the P/E. If not, then existing shareholders might be a little nervous about the viability of the share price.
See our latest analysis for Instituto Hermes Pardini
Is There Enough Growth For Instituto Hermes Pardini?
Instituto Hermes Pardini's P/E ratio would be typical for a company that's expected to deliver very strong growth, and importantly, perform much better than the market.
Retrospectively, the last year delivered an exceptional 18% gain to the company's bottom line. EPS has also lifted 20% in aggregate from three years ago, mostly thanks to the last 12 months of growth. Accordingly, shareholders would have probably been satisfied with the medium-term rates of earnings growth.
Looking ahead now, EPS is anticipated to climb by 6.9% per annum during the coming three years according to the four analysts following the company. With the market predicted to deliver 13% growth each year, the company is positioned for a weaker earnings result.
In light of this, it's alarming that Instituto Hermes Pardini's P/E sits above the majority of other companies. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. There's a good chance these shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the growth outlook.
The Bottom Line On Instituto Hermes Pardini's P/E
Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.
We've established that Instituto Hermes Pardini currently trades on a much higher than expected P/E since its forecast growth is lower than the wider market. Right now we are increasingly uncomfortable with the high P/E as the predicted future earnings aren't likely to support such positive sentiment for long. Unless these conditions improve markedly, it's very challenging to accept these prices as being reasonable.
Having said that, be aware Instituto Hermes Pardini is showing 1 warning sign in our investment analysis, you should know about.
If these risks are making you reconsider your opinion on Instituto Hermes Pardini, explore our interactive list of high quality stocks to get an idea of what else is out there.
If you’re looking to trade Instituto Hermes Pardini, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
About BOVESPA:PARD3
Instituto Hermes Pardini
Instituto Hermes Pardini S.A., together with its subsidiaries, provides medical, dental, laboratory research, clinical analysis, and supplementary diagnostic and therapeutic services in Brazil.
Adequate balance sheet second-rate dividend payer.
Market Insights
Community Narratives
